| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 28, 2006
Accepted on November 19, 2006
From Molecular Cardiology, Department of Internal Medicine III (D.H.W., U.R., J.R., F.S., A.A, C.U., I.S., A.M.Z., S.D., J.H.), University of Frankfurt, Germany; the Department of Molecular Biology (J.C.), Helen L. Dorris Child and Adolescent Neuropsychiatric Disorder Institute, The Scripps Research Institute, La Jolla, Calif; the Institute of Pathophysiology (P.K., B.L.), Center of Internal Medicine, Essen, Germany; and the Novartis Institute for Biomedical Research (V.B.), Basel, Switzerland.
* To whom correspondence should be addressed. E-mail: j.haendeler{at}em.uni-frankfurt.de.
Objective--Sphingosine-1-phosphate (S1P) is a bioactive lipid, which influences migration and proliferation of endothelial cells through activation of S1P receptors and has been shown to support SDF-1 induced migration and bone marrow homing of CD34+ progenitors.
Methods and Results--Here, we show that incubation of patient derived endothelial progenitor cells (EPCs) with S1P or its synthetic analog FTY720 improved blood flow recovery in ischemic hind limbs. Likewise, recovery of blood flow was dramatically reduced after induction of hindlimb ischemia in mice deficient for the S1P receptor 3 (S1P3). S1P3-/- bone marrow-derived mononuclear cells (BMCs) failed to augment neovascularization after hind limb ischemia. Of note, treatment of BMCs derived from S1P3-/- mice with S1P did not rescue blood flow recovery. Mechanistically, S1P and FTY720 induced phosphorylation of CXCR4, activated the Src kinase, and stimulated phosphorylation of JAK2. The contribution of the CXCR4 for S1P-mediated effects was further supported by the findings that S1P preincubation failed to stimulate invasion capacity and in vivo blood flow recovery of BMCs from CXCR4+/- mice. The activation of CXCR4 was dependent on the Src kinase family as demonstrated by preincubation with the Src inhibitor PP2. The activation of the CXCR4 signaling by S1P is mediated via the S1P3 receptor, since S1P-induced Src phosphorylation was abrogated in EPC from S1P3-/- mice.
Conclusions--S1P agonists might serve as sensitizers of CXCR4-mediated signaling and may be applied in clinical progenitor cell therapy to improve EPC or BMC function in patients with coronary artery disease.
Related Article:
This article has been cited by other articles:
![]() |
K. Sattler and B. Levkau Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection Cardiovasc Res, May 1, 2009; 82(2): 201 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Bonder, W. Y. Sun, T. Matthews, C. Cassano, X. Li, H. S. Ramshaw, S. M. Pitson, A. F. Lopez, P. T. Coates, R. L. Proia, et al. Sphingosine kinase regulates the rate of endothelial progenitor cell differentiation Blood, February 26, 2009; 113(9): 2108 - 2117. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Feng, M. van Eck, E. Van Craeyveld, F. Jacobs, V. Carlier, S. Van Linthout, M. Erdel, M. Tjwa, and B. De Geest Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer Blood, January 15, 2009; 113(3): 755 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Foubert, G. Matrone, B. Souttou, C. Lere-Dean, V. Barateau, J. Plouet, S. Le Ricousse-Roussanne, B. I. Levy, J.-S. Silvestre, and G. Tobelem Coadministration of Endothelial and Smooth Muscle Progenitor Cells Enhances the Efficiency of Proangiogenic Cell-Based Therapy Circ. Res., September 26, 2008; 103(7): 751 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dimmeler and A. Leri Aging and Disease as Modifiers of Efficacy of Cell Therapy Circ. Res., June 6, 2008; 102(11): 1319 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Oyama, N. Sugimoto, X. Qi, N. Takuwa, K. Mizugishi, J. Koizumi, and Y. Takuwa The lysophospholipid mediator sphingosine-1-phosphate promotes angiogenesis in vivo in ischaemic hindlimbs of mice Cardiovasc Res, May 1, 2008; 78(2): 301 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Zemani, J.-S. Silvestre, F. Fauvel-Lafeve, A. Bruel, J. Vilar, I. Bieche, I. Laurendeau, I. Galy-Fauroux, A. M. Fischer, and C. Boisson-Vidal Ex Vivo Priming of Endothelial Progenitor Cells With SDF-1 Before Transplantation Could Increase Their Proangiogenic Potential Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 644 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shimokawa Bone Marrow-Derived Matrix Metalloproteinase-14: A Novel Target for Plaque Stability Circulation, February 19, 2008; 117(7): 863 - 865. [Full Text] [PDF] |
||||
![]() |
K. Satoh and B. C. Berk Circulating smooth muscle progenitor cells: novel players in plaque stability Cardiovasc Res, February 1, 2008; 77(3): 445 - 447. [Full Text] [PDF] |
||||
![]() |
T. H. Westhoff, S. Schmidt, P. Glander, L. Liefeld, S. Martini, G. Offermann, H. H. Neumayer, W. Zidek, M. van der Giet, and K. Budde The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2354 - 2358. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sainz and M. Sata CXCR4, a Key Modulator of Vascular Progenitor Cells Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 263 - 265. [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |